奧卡西平致 HLA-B*1502 陰性癲癇患者非剝脫性皮疹一例_Journal of Epilepsy

Authors：

莫聽 ,  楊興隆

昆明醫科大學第一附屬醫院老年神經內科（昆明 650000）;

Corresponding?author：

楊興隆, Email: yxldoc11@163.com

Keywords：

DOI：

10.7507/2096-0247.20200078

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 莫聽, 楊興隆. 奧卡西平致 HLA-B*1502 陰性癲癇患者非剝脫性皮疹一例. Journal of Epilepsy, 2020, 6(5): 470-472. doi: 10.7507/2096-0247.20200078 Copy

1.	王清香, 賈淑梅. 奧卡西平結合心理療法治療青少年癲癇120例療效觀察. 安徽醫藥, 2019, 23(4): 812.
2.	陳艷平, 魯虹, 史群志, 等. 高效液相色譜法測定人血漿中奧卡西平及其活性代謝產物的濃度. 中南藥學, 2016, 14(6): 616-619.
3.	陳新謙, 金有豫, 湯光. 新編藥物學. 第16 版. 北京: 人民衛生出版社, 2007: 221.
4.	Kaufman DW, Shapiro S. Epidemiological assessment of druginduced disease. Lancet, 2000, 356(9238): 1339-1343.
5.	Arif H, Buchsbaum R, Weintraub D, <italic>et al</italic>. Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology, 2007, 68(20): 1701-1709.
6.	Pratoomsri W, Yatham LN, Bond DJ, <italic>et al</italic>. Oxcar- bazepine in the treatment of bipolar disorder: a review. Can J Psychiatry, 2006, 51(8): 540-545.
7.	江帆. 美國(版)奧卡西平說明書中增加新的警告. 中國藥師, 2006, 9(6): 571.
8.	Chen M, Yang B, Wang C, <italic>et al</italic>. Oxcarbazepine-induced Stevens-Johnson syndrome in a patient with HLA-B*1502 genotype. Australas J Dermatol, 2016, 57(4): e137-e138.
9.	Hung SI, Chung WH, Chen YT. HLA-B genotyping to detect carbamazepine-induced Stevens-Johnson syndrome:Implications for personalizing medicine. Personal Med, 2005, 2(3): 225-237.
10.	Laska AJ, Han MJ, Lospinoso JA, <italic>et al</italic>. Brown PJ, Beachkofsky TM. CYP2C19*2 status in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmgenomics Pers Med, 2017, 10: 183-186.
11.	Franco V, Perucca E. The pharmacogenomics of epilepsy. Expert Rev Neurother, 2015, 15(10): 1161-1170.
12.	韓翔宇, 王菊莉, 曹洪濤, 等. 奧卡西平誘發輕微皮膚不良反應與 HLA 等位基因相關性的研究. 黑龍江醫藥科學, 2016, 39(1): 39-40.
13.	Tangamornsuksan W, Scholfield N, Lohitnavy M. Association between HLA genotypes and oxcarbazepine-induced cutaneous adverse drug reactions: a systematic reviewand meta-analysis. J Pharm Pharm Sci, 2018, 21(1): 1-18.
14.	Chung WH, Hung SI. Recent advances in the genetics and immunology of Stevens-Johnson syndrome and toxic epidermal necrosis. J Der- matol Sci, 2012, 66(3): 190-196.
15.	Zeng T, Long YS, Min FL, <italic>et al</italic>. Association of HLA-B*1502 allele with lamotrigine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in han Chinese subjects: a meta-analysis. Int J Dermatol, 2015, 54(4): 488-493.
16.	Choi H, Mohit B. Cost-effectiveness of screening for HLA-B*1502 prior to initiation of carbamazepine in epilepsy patients of asian ancestry in the united states. Epilepsia, 2019, 60(7): 1472-1481.

1. 王清香, 賈淑梅. 奧卡西平結合心理療法治療青少年癲癇120例療效觀察. 安徽醫藥, 2019, 23(4): 812.
2. 陳艷平, 魯虹, 史群志, 等. 高效液相色譜法測定人血漿中奧卡西平及其活性代謝產物的濃度. 中南藥學, 2016, 14(6): 616-619.
3. 陳新謙, 金有豫, 湯光. 新編藥物學. 第16 版. 北京: 人民衛生出版社, 2007: 221.
4. Kaufman DW, Shapiro S. Epidemiological assessment of druginduced disease. Lancet, 2000, 356(9238): 1339-1343.
5. Arif H, Buchsbaum R, Weintraub D, <italic>et al</italic>. Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology, 2007, 68(20): 1701-1709.
6. Pratoomsri W, Yatham LN, Bond DJ, <italic>et al</italic>. Oxcar- bazepine in the treatment of bipolar disorder: a review. Can J Psychiatry, 2006, 51(8): 540-545.
7. 江帆. 美國(版)奧卡西平說明書中增加新的警告. 中國藥師, 2006, 9(6): 571.
8. Chen M, Yang B, Wang C, <italic>et al</italic>. Oxcarbazepine-induced Stevens-Johnson syndrome in a patient with HLA-B*1502 genotype. Australas J Dermatol, 2016, 57(4): e137-e138.
9. Hung SI, Chung WH, Chen YT. HLA-B genotyping to detect carbamazepine-induced Stevens-Johnson syndrome:Implications for personalizing medicine. Personal Med, 2005, 2(3): 225-237.
10. Laska AJ, Han MJ, Lospinoso JA, <italic>et al</italic>. Brown PJ, Beachkofsky TM. CYP2C19*2 status in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmgenomics Pers Med, 2017, 10: 183-186.
11. Franco V, Perucca E. The pharmacogenomics of epilepsy. Expert Rev Neurother, 2015, 15(10): 1161-1170.
12. 韓翔宇, 王菊莉, 曹洪濤, 等. 奧卡西平誘發輕微皮膚不良反應與 HLA 等位基因相關性的研究. 黑龍江醫藥科學, 2016, 39(1): 39-40.
13. Tangamornsuksan W, Scholfield N, Lohitnavy M. Association between HLA genotypes and oxcarbazepine-induced cutaneous adverse drug reactions: a systematic reviewand meta-analysis. J Pharm Pharm Sci, 2018, 21(1): 1-18.
14. Chung WH, Hung SI. Recent advances in the genetics and immunology of Stevens-Johnson syndrome and toxic epidermal necrosis. J Der- matol Sci, 2012, 66(3): 190-196.
15. Zeng T, Long YS, Min FL, <italic>et al</italic>. Association of HLA-B*1502 allele with lamotrigine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in han Chinese subjects: a meta-analysis. Int J Dermatol, 2015, 54(4): 488-493.
16. Choi H, Mohit B. Cost-effectiveness of screening for HLA-B*1502 prior to initiation of carbamazepine in epilepsy patients of asian ancestry in the united states. Epilepsia, 2019, 60(7): 1472-1481.

Previous Article
癔癥性抽搐誤診為癲癇一例

Journal of Epilepsy

奧卡西平致 HLA-B*1502 陰性癲癇患者非剝脫性皮疹一例

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Format

Content